CHL Medical Partners

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

CareWell Urgent Care is a provider of emergency healthcare services based in Tewksbury, Massachusetts, with multiple centers operating in the New England area. The organization focuses on delivering accessible and efficient urgent care for a variety of common illnesses and injuries, including cold infections, fractures, rashes, nosebleeds, chronic conditions, and skin diseases. CareWell Urgent Care offers on-site laboratory services, X-ray capabilities, and the ability to dispense common medications, enabling patients to receive timely treatment without the need for an appointment.

Ambra Health is a medical data and image management company that provides a cloud-based platform designed to enhance the accessibility and management of medical images. The platform is intuitive, flexible, and scalable, enabling healthcare providers, including prominent health systems and clinical research organizations, to improve their imaging workflows and collaborative care. By offering secure and straightforward access to medical images, Ambra Health facilitates better internal adoption and collaboration among healthcare professionals. This capability allows organizations to significantly enhance their operational efficiency and patient care outcomes by making medical images and data accessible from anywhere.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

Ambra Health is a medical data and image management company that provides a cloud-based platform designed to enhance the accessibility and management of medical images. The platform is intuitive, flexible, and scalable, enabling healthcare providers, including prominent health systems and clinical research organizations, to improve their imaging workflows and collaborative care. By offering secure and straightforward access to medical images, Ambra Health facilitates better internal adoption and collaboration among healthcare professionals. This capability allows organizations to significantly enhance their operational efficiency and patient care outcomes by making medical images and data accessible from anywhere.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis (LSS). Founded in 2005 and headquartered in Aliso Viejo, California, the company has developed the mild device, which provides an outpatient, fluoroscopically guided treatment for LSS without the need for implants. This innovative approach allows physicians to perform lumbar decompression procedures under local anesthesia, helping to restore space in the spinal canal, alleviate pressure on nerves, and enhance patient mobility. Vertos Medical's commitment to advancing spinal care is reflected in its focus on delivering effective solutions for common spinal diseases.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis (LSS). Founded in 2005 and headquartered in Aliso Viejo, California, the company has developed the mild device, which provides an outpatient, fluoroscopically guided treatment for LSS without the need for implants. This innovative approach allows physicians to perform lumbar decompression procedures under local anesthesia, helping to restore space in the spinal canal, alleviate pressure on nerves, and enhance patient mobility. Vertos Medical's commitment to advancing spinal care is reflected in its focus on delivering effective solutions for common spinal diseases.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

North American Scientific is engaged in the design, development, manufacture, and sale of radioisotopic products for the treatment of cancer. The company offers Prospera I-125, an iodine-based seed and Prospera Pd-103, a palladium-based seed for the treatment of prostate cancer; SurTRAK needles and strands used primarily for the treatment of prostate cancer; and STP-110 Precision Stepper and RTP-6000 Precision Stabilizer equipment, which positions and holds the trans-rectal ultrasound probe during the LDR brachytherapy procedure as well as radiation shielding and needle loading accessories such as horizontal needle box; and needle-loading shield, box, and carousel. The company also offers ClearPath, a multi-catheter breast brachytherapy device for accelerated partial breast irradiation treatment for women with early-stage breast cancer. North American Scientific was founded in 1987 and is based in Chatsworth, California, United States.

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

BIKAM Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. BIKAM's research centers on small molecule, non-retinoid pharmacological chaperones designed to address issues related to misfolded proteins within the retina. Their lead product is an orally active pharmacological chaperone that targets misfolded rod opsin, which is implicated in retinitis pigmentosa, helping to correct its trafficking to the rod cell surface and outer segment. Through its innovative approach, BIKAM Pharmaceuticals strives to provide new treatment options for patients suffering from these serious retinal conditions.

Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.

OpGen, Inc. is a precision medicine company focused on developing molecular diagnostics and informatics to address infectious diseases. Headquartered in Gaithersburg, Maryland, OpGen offers a range of products designed to provide clinicians with rapid and actionable information regarding life-threatening infections, ultimately aiming to enhance patient outcomes and reduce the spread of multidrug-resistant organisms (MDROs). Its key offerings include the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance, and the QuickFISH and PNA FISH products for pathogen identification in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient and hospital data to support the management of antimicrobial-resistant infections. The company collaborates with the New York State Department of Health to develop solutions for detecting and tracking such infections in healthcare settings. Established in 2001, OpGen continues to innovate in addressing the critical challenge of antibiotic resistance through its advanced molecular microbiology solutions.

Millennium Pharmacy Systems is a pharmacy services provider focused on the long-term care industry. Headquartered in Chicago, Illinois, the company offers a unique approach to pharmacy services by integrating Just-In-Time Dispensing with electronic prescription ordering, formulary management, and comprehensive medication administration. This combination enables nursing and assisted living communities to enhance patient care while effectively reducing costs and improving operational efficiency. Millennium's commitment to timely delivery and medication accuracy is reflected in its customer guarantees, supporting clients in meeting compliance requirements more easily.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Ascend Health Corporation is a behavioral healthcare provider that specializes in a comprehensive range of inpatient and day hospital services for individuals across various age groups, including children, adolescents, adults, and seniors. The organization operates freestanding psychiatric hospitals and offers a wide array of behavioral health programs, such as residential treatment centers, partial hospitalization, and intensive outpatient services. Ascend Health emphasizes personal choice and tailored care, ensuring that its services are effectively integrated with the local healthcare systems to deliver high-quality treatment for mental health and substance abuse issues.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Cantex Pharmaceuticals is a biotechnology company focused on developing innovative cancer treatments by modifying existing therapies. The company has two primary development programs that utilize known chemical entities to address significant unmet medical needs in oncology. One of its key products is ODSH, a low anticoagulant heparin derivative aimed at mitigating the adverse effects of chemotherapy on platelet counts. Additionally, Cantex offers Disulfiram-Copper Chelate, which employs multiple mechanisms to target cancer stem cells, making it a potential treatment option for metastatic breast cancer, pancreatic cancer, and glioblastoma. Established in 2002 and based in Weston, Florida, Cantex Pharmaceuticals is dedicated to creating safer and more effective therapeutic options for patients facing life-threatening disorders.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Oculir develops non-invasive glucose meter that measures glucose from the conjunctiva of the eye.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Millennium Pharmacy Systems is a pharmacy services provider focused on the long-term care industry. Headquartered in Chicago, Illinois, the company offers a unique approach to pharmacy services by integrating Just-In-Time Dispensing with electronic prescription ordering, formulary management, and comprehensive medication administration. This combination enables nursing and assisted living communities to enhance patient care while effectively reducing costs and improving operational efficiency. Millennium's commitment to timely delivery and medication accuracy is reflected in its customer guarantees, supporting clients in meeting compliance requirements more easily.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

GeneOhm Sciences is a company that designs, develops, and delivers nucleic acid-based diagnostic solutions aimed at addressing unmet diagnostic needs across various diseases, including inherited diseases, infectious diseases, and oncology. Based in San Diego, California, and established in 2001, GeneOhm focuses on developing rapid diagnostic systems that can detect and identify infectious agents and genetic variations, providing results in under two hours. The company offers specific diagnostic tests, including an assay for methicillin-resistant Staphylococcus aureus (MRSA) and a test for Group B Streptococcus in pregnant women. Additionally, GeneOhm's technology includes a lysis kit for processing various sample types. In 2004, GeneOhm merged with Infectio Diagnostic, Inc., enhancing its portfolio with proprietary technology and industry expertise. The company was later acquired by the BD Pharmaceuticals group, further solidifying its position in the molecular diagnostics field.

GeneOhm Sciences is a company that designs, develops, and delivers nucleic acid-based diagnostic solutions aimed at addressing unmet diagnostic needs across various diseases, including inherited diseases, infectious diseases, and oncology. Based in San Diego, California, and established in 2001, GeneOhm focuses on developing rapid diagnostic systems that can detect and identify infectious agents and genetic variations, providing results in under two hours. The company offers specific diagnostic tests, including an assay for methicillin-resistant Staphylococcus aureus (MRSA) and a test for Group B Streptococcus in pregnant women. Additionally, GeneOhm's technology includes a lysis kit for processing various sample types. In 2004, GeneOhm merged with Infectio Diagnostic, Inc., enhancing its portfolio with proprietary technology and industry expertise. The company was later acquired by the BD Pharmaceuticals group, further solidifying its position in the molecular diagnostics field.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Eunoe, Inc. is a San Francisco Bay-area medical device company focused on the treatment of neurological disorders through the management of cerebrospinal fluid.

LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

RxCentric is an e-health company that specializes in providing online marketing solutions for pharmaceutical companies. It connects physicians with essential drug information and educational resources through a targeted digital platform. By offering rapid access to comprehensive and reliable drug information, RxCentric aims to enhance the educational needs of healthcare professionals and improve their decision-making processes regarding pharmaceutical products.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

RxCentric is an e-health company that specializes in providing online marketing solutions for pharmaceutical companies. It connects physicians with essential drug information and educational resources through a targeted digital platform. By offering rapid access to comprehensive and reliable drug information, RxCentric aims to enhance the educational needs of healthcare professionals and improve their decision-making processes regarding pharmaceutical products.

Protometrix develops integrated proteomics technologies to improve human health. Protometrix focuses on the production and investigation of the function and interaction of proteins in parallel using nanoscale technology and collection of information in an informatics database.

Molecular Staging, Inc. is a life sciences tool company focused on developing technologies for the detection and measurement of proteins and nucleic acids. Its offerings encompass various applications in proteomics, genomics, pharmacogenomics, and diagnostics. Notable products include protein microarrays, which allow researchers to analyze multiple proteins simultaneously, and whole-genome amplification technology that addresses challenges posed by limited DNA sample quantities. Additionally, the company provides multiplexed diagnostics, facilitating the earlier detection of diseases and enhancing confirmatory diagnoses. Through these innovations, Molecular Staging supports advancements in research and clinical applications.

Lifespire was created in late 1999 through the merging of 2 companies: Vida Healthcare and inspiria.com. Vida Healthcare, formed in 1996, has worked with hundreds of oncology doctors, nurses and allied health professionals to improve cancer care. Lifespire Their vision is to improve care through shared knowledge. But what does that mean to you, the patient, and your circle of family and friends They serve? It means that They are giving you and the ones closest to you -- your circle of care -- a resource for gathering credible knowledge, support and understanding of your experience with cancer. Some of you may have known us when They were Vida Healthcare. In Their four years as Vida, They delivered clinical support and education services to over 4,000 people experiencing cancer. Now They're bringing that experience and understanding to you. They're doing this in partnership with companies committed to improving the treatment of cancer. And They're using Lifespire.com as Their forum for delivery.

RxCentric is an e-health company that specializes in providing online marketing solutions for pharmaceutical companies. It connects physicians with essential drug information and educational resources through a targeted digital platform. By offering rapid access to comprehensive and reliable drug information, RxCentric aims to enhance the educational needs of healthcare professionals and improve their decision-making processes regarding pharmaceutical products.

ICOS Corporation is a biotechnology company that engages in the discovery, development, and commercialization of therapeutic products. It is engaged in the commercialization of treatments for unmet medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. It is the developer of a treatment known as Cialis (tadalafil), a product for the treatment of erectile dysfunction through its joint venture with Eli Lilly and Company in North America and Europe. It is also engaged in contract manufacturing services for third parties. It is in a strategic alliance with Solvay Pharmaceuticals, Inc. ICOS Corporation was established in 1989, based in Bothell, Washington. It is currently operated by Eli Lilly and Company.